Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes

Current Opinion in Investigational Drugs

Volumn 3, Issue 11, 2002, Pages 1608-1616

  Liu, Gang ^a   Trevillyan, James M ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Cellular permeability; Impaired glucose tolerance; Insulin sensitizer; Insulin signaling; Phosphotyrosyl mimetic; Protein tyrosine phosphatase; Structure based drug design; Type II diabetes

Indexed keywords

2 OXALYLAMINOBENZOIC ACID; AMINOBENZOIC ACID DERIVATIVE; ANTIDIABETIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BENZOXATHIOAZOLE DERIVATIVE; FAT; FENOFIBRATE; GLUCOSE; GLUTAMYL PHOSPHONODIFLUOROMETHYLPHENYLALANINE PHOSPHONODIFLUOROMETHYLPHENYLALANINE; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR; O CARBOXYMETHYL SALICYLIC ACID DERIVATIVE; PHENOXYACETIC ACID DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PTP 112; ROSIGLITAZONE; SULFONYLSALICYLIC ACID DERIVATIVE; THIENO[2,3 C]PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

BLOOD GLUCOSE MONITORING; CATALYSIS; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; COMBINATORIAL LIBRARY; DIET; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME DEFICIENCY; FAT CONTENT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; LIVER LEVEL; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RECEPTOR BINDING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; PROTEIN-TYROSINE-PHOSPHATASE;

EID: 0036881742     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Burke TR, Zhang Z-Y: Protein tyrosine phosphatases: Structure, mechanism, and inhibitor discovery. Biopolymers (1998) 47:225-241.
2. Ripka WC: Protein tyrosine phosphatase inhibition. Annu Rep Med Chem (2000) 35:231-250.
3. Moller NP, Iversen LF, Andersen HS, McCormack JG: Protein tyrosine phosphatases (PTPs) as drug targets: Inhibitors of PTP1B for the treatment of diabetes. Curr Opin Drug Discovery Dev (2000) 3(5):527-540. Good review on Novo Nordisk's rational approach for designing potent and selective PTPase inhibitors.
4. Kruszynska YT, Olefsky JM: Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. J Invest Med (1996) 44(8):413-428.
5. Youngren JF, Goldfine ID: The molecular basis of insulin resistance. Science Med (1997) 4:18-27.
6. Olefsky JM, Garvey WT, Henry RR, Brillon D, Matthaei S, Freidenberg GR: Cellular mechanisms of insulin resistance in non-insulin dependent (Type II) diabetes. Am J Med (1998) 85(5A):86-105.
7. Kahn CR: Insulin action, diabetogenes, and the cause of Type II diabetes. Diabetes (1994) 43(8):1066-1084.
8. Herrera R, Rosen OM: Autophosphorylation of the insulin receptor in vitro: Designation of phosphorylation sites and correlation with receptor kinase activation. J Biol Chem (1986) 261(26):11980-11985.
9. Olefsky JM: Insulin-stimulated glucose transport minireview series. J Biol Chem (1999) 274(4):1863.
10. White MF: The IRS-signaling system: A network of docking proteins that mediate insulin action. Mol Cell Biochem (1998) 182(1-2):3-11.
11. Kao AW, Waters SB, Okada S, Pessin JE: Insulin stimulates the phosphorylation of the 66- and 52-kiloDalton Shc isoforms by distinct pathways. Endocrinology (1997) 138(6):2474-2480.
12. Czech MP, Corvera S: Signaling mechanisms that regulate glucose transport. J Biol Chem (1999) 274(4):1865-1868.
13. Kenner KA, Anyanwu E, Olefsky JM, Kusari J: Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling. J Biol Chem (1996) 271(33):19810-19819.
14. Chen H, Wertheimer SJ, Lin CH, Katz SL, Amrein KE, Burn P, Quon MJ: Protein-tyrosine phosphatases PTP1B and Syp are modulators of insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. J Biol Chem (1997) 272(12): 8026-8031.
15. Ahmad F, Li PM, Meyerovitch J, Goldstein BJ: Osmotic loading of neutralizing antibodies demonstrates a role for protein-tyrosine phosphatase 1B in negative regulation of the insulin action pathway. J Biol Chem (1995) 270(35):20503-20508.
16. Chen H, Cong LN, Li Y, Yao ZJ, Wu L, Zhang ZY, Burke TR, Quon MJ: A phosphotyrosyl mimetic peptide reverses impairment of insulin-stimulated translocation of Glut4 caused by overexpression of PTP1B in rat adipose cells. Biochemistry (1999) 38(1):384-389.
17. Frangioni JV, Beahm PH, Shifrin V, Jost CA, Neel BG: The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell (1992) 68(3):545-560.
18. Walchli S, Curchod ML, Gobert RP, Arkinstall S, Hooft Van Huijsduijnen R: Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. J Biol Chem (2000) 275(13):9792-9796.
19. Goldstein BJ, Bittner-Kowalczyk A, White MF, Harbeck M: Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. J Biol Chem (2000) 275(6):4283-4289.
20. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran C et al: Increased insulin sensitivity and obesity resistance in mice lacking the protein-tyrosine phosphatase-1B gene. Science (1999) 283(5407):1544-1548. A landmark paper in the study of the physiological roles PTP1B plays that firmly establishes PTP1B as an attractive drug discovery target for Type II diabetes.
21. Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabotny JM, Moghal N, Lubkin M, Kim Y.-B, Sharpe AH, Stricker-Krongrad A, Shulman GI, Neel BG, Kahn BB: Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol (2000) 20 (15):5479-5489. A confirmation and extension of the findings by Elchebly and co-workers [20]. This paper also demonstrates that resistance to diet-induced obesity is due to an increase in energy expenditure.
22. Ahmad F, Azevedo JL, Cortright R, Dohm GL, Goldstein BJ: Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest (1997) 100(2):449-458.
23. Ahmad F, Considine RV, Bauer TL, Ohannesian JP, Marco CC, Goldstein B.J: Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Metabolism (1997) 46(10):1140-1145.
24. Worm D, Vinten J, Staehr P, Henriksen JE, Handberg A, Beck-Nielsen H: Altered basal and insulin-stimulated phosphotyrosine phosphatase (PTPase) activity in skeletal muscle from NIDDM patients compared with control subjects. Diabetologia (1996) 39(10):1208-1214.
25. Kusari J, Kenner KA, Suh KI, Hill DE, Henry RR: Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance. J Clin Invest (1994) 93(3):1156-1162.
26. Cheung A, Kusari J, Jansen D, Bandyopadhyay D, Kusari A, Bryer-Ash M: Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus. J Lab Clin Med (1999) 134(2):115-123.
27. Di Paola R, Frittitta L, Miscio G, Bozzali M, Baratta R, Centra M, Spampinato D, Santagati MG, Ercolino T, Cisternino C, Soccio T et al: A variation in 3′ UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet (2002) 70(3):806-812.
28. Echwald SM, Bach H, Vestegaard H, Richelsen B, Kristensen K, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O: A P387L variant in protein-tyrosine phosphatase 1B (PTP1B) is associated with Type 2 diabetes and impaired serine phosphorylation of PTP1B in vitro. Diabetes (2002) 51(1):1-6.
29. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, Haj F, Wang Y, Minokoshi Y, Kim YB, Elmquist JK, Tartaglia LA, Kahn BB, Neel BG: PTP1B regulates leptin signal transduction in vivo. Dev Cell (2002) 2(4):489-495.
30. Kaszubska W, Falls H, Schaefer V, Haasch D, Frost L, Hessler P, Kroeger P, White D, Jirousek M, Trevillyan J: Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line. Mol Cell Endocrinol (2002) 195(1-2):109.
31. Myers MP, Andersen JN, Cheng A, Tremblay ML, Horvath CM, Parisien J.-P, Salmeen A, Barford D Tonks NK: Tyk2 and Jak2 are substrates of protein tyrosine phosphatase 1B. J Biol Chem (2001) 276(51):47771-47774.
32. Flint AJ, Tiganis T, Barford D, Tonks NK: Development of 'substrate-trapping' mutants to identify physilogical substrates of protein tyrosine phosphatases. Proc Natl Acad Sci USA (1997) 94(5):1680-1685.
33. Balsamo J, Arregui C, Leung T, Lilien J: The nonreceptor protein tyrosine phosphatase PTP1B binds to the cytoplasmic domain of N-cadherin and regulates the cadherin-actin linkage. J Cell Biol (1998) 143(2):523-532.
34. Arregui, CO, Balsamo J, Lilien J: Impaired integrin-mediated adhesion and signaling in fibroblasts expressing a dominant-negative mutant PTP1B. J Cell Biol (1998) 143(3):861-873.
35. Liu F, Hill DE, Chernoff J: Direct binding of the proline-rich region of protein-tyrosine phosphatase 1B to the Src homology 3 domain of p130 (Cas). J Biol Chem (1996) 271(49):31290-31295
36. Liu F, Sells MA, Chernoff J: Protein-tyrosine phosphatase 1B negatively regulates integrin signalling. Curr Biol (1998) 8(3):173-176.
37. Schievella AR, Paige LA, Johnson KA, Hill DE, Erikson RL: Protein tyrosine phosphatase 1B undergoes mitosis-specific phosphorylation on serine. Cell Growth Differ (1993) 4(4):239-246.
38. Flint AJ, Gebbink MF, Franza BR, Hill DE, Tonks NK: Multi-site phosphorylation of the protein tyrosine phosphatase, PTP1B: Identification of cell cycle regulated and phorbol ester stimulated sites of phosphorylation. EMBO J (1993) 12:1937-1946.
39. Shifrin VI, Davis RJ, Neel BG: Phosphorylation of protein-tyrosine phosphatase PTP-1B on identical sites suggests activation of a common signaling pathway during mitosis and stress response in mammalian cells. J Biol Chem (1997) 272(5):2957-2962.
40. Kennedy BP, Ramachandran C: Protein-tyrosine phosphatase 1B in diabetes. Biochem Pharmacol (2000) 60(7):877-883.
41. You-Ten KE, Muise ES, Itié A, Michaliszyn E, Wagner J, Jothy S, Lapp WS, Tremblay ML: Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med (1997) 186(5):683-693.
42. Saxton TM, Henkemeyer M, Gasca S, Shen R, Rossi DJ, Shalaby F, Feng G-S, Pawson T: Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J (1997) 16(9):2352-2364.
43. D'Ambrosio D, Hippen KL, Minskoff SA, Mellman I, Pani G, Siminovitch KA, Cambier JC. Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by FcRIIB1. Science (1995) 268(5208):293-297.
44. Kishihara K, Penninger J, Wallace VA, Kündig TM, Kawai K, Wakeham A, Timms E, Pfeffer K, Ohashi PS, Thomas ML, Furlonger C, Paige CJ, Mak TW: Normal B lymphocyte development but impaired T cell maturation in CD45-exon 6 protein tyrosine phosphatase-deficient mice. Cell (1993) 74(1):143-156.
45. Schaapveld RQJ, Schepens JTG, Robinson GW, Attema J, Oerlemans FTJJ, Fransen JAM, Streuli M, Wieringa B, Hennighausen L, Hendriks WJAJ: Impaired mammary gland development and function in mice lacking LAR receptor-like tyrosine phosphatase activity. Dev Biol (1997) 188(1):134-146.
46. Ren JM, Li PM, Zhang WR, Sweet LJ, Cline G, Shulman GI, Livingston JN, Goldstein BJ: Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes (1998) 47(3):493-497.
47. Côté J-F, Charest A, Wagner J, Tremblay ML: Combination of gene targeting and substrate trapping to identify substrates of protein tyrosine phosphatase using PTP-PEST as a model. Biochemistry (1998) 37(38):13128-13137.
48. Elchebly M, Wagner J, Kennedy TE, Lanctot C, Michaliszyn E, Itié A, Drouin J, Tremblay ML: Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase. Nat Genet (1999) 21(3):330-333.
49. Puius YA, Zhao Y, Sullivan M, Lawrence DS, Almo SC, Zhang Z-Y: Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design. Proc Natl Acad Sci USA (1997) 94(25):13420-13425. The first paper establishing the existence of a second phosphotyrosyl-binding site outside of the catalytic site. It also demonstrates that selective PTP1B inhibitors can be obtained by addressing regions outside the catalytic site binding pocket.
50. Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D: Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Mol Cell (2000) 6(6):1401-1412. A key paper describing the interaction between an IR activation loop-based peptide and PTP1B.
51. Bruke TR, Yao Z-J, Liu D-G, Voigt J, Gao Y: Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors. Biopolymers (2001) 60(1):32-44.
52. 2PMP. Biochem Biophys Res Commun (1994) 204(1):129-134.
53. Roller PP, Wu L, Zhang Z-Y, Burke TR: Potent inhibition of protein-tyrosine phosphatase-1B using the phosphotyrosyl mimetic fluoro-O-malonyl tyrosine (FOMT). Bioorg Med Chem Lett (1998) 8(16):2149-2150.
54. Beaulieu PL, Cameron DR, Ferland J-M, Gauthier J, Ghiro E, Gillard J, Gorys V, Poirier M, Rancourt J, Wernic D, Llinas-Brunet M et al: Ligands for the tyrosine kinase p56lck SH2 domain: Discovery of potent dipeptide derivatives with monocharged, nohydrolyzable phosphate replacements. J Med Chem (1999) 42(10):1757-1766.
55. Chen L, Wu L, Otaka A, Smyth MS, Roller PP, Burke TR, Den Hertog J, Zhang Z-Y: Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases? Biochem Biophys Res Commun (1995) 216(3):976-984.
56. Desmarais S, Friesen RW, Zamboni R, Ramachandran C: [Difluro(phosphono)methyl]phenylalanine-containing peptide inhibitors of protein tyrosine phosphatases. Biochem J (1999) 337(Pt 2):219-223.
57. Shen K, Keng YF, Wu L, Guo XL, Lawrence DS, Zhang Z-Y: Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J Biol Chem (2001) 276(50):47311-47319.
58. Jia Z, Ye Q, Dinaut AN, Wang Q, Waddleton D, Payette P, Ramachandran C, Kennedy B, Hum G, Taylor SD: Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics. J Med Chem (2001) 44(26):4584-4594.
59. Stankovic CJ, Surendran N, Lunney EA, Plummer MS, Para KS, Shahripour A, Fergus JH, Marks JS, Herrera R, Hubbell SE, Humblet C et al: The role of 4-phosphonodifluoromethyl- and 4-phosphonophenylalanine in the selectivity and cellular uptake of SH2 domain ligands. Bioorg Med Chem Lett (1997) 7:1909-1914.
60. Liu S, Dockendorf C, Taylor SD: Synthesis of protected L-4-[sulfono(difluoromethyl)]phenylalanine and its incorporation into a peptide. Org Lett (2001) 3:1571-1575.
61. Wrobel J, Sredy J, Moxham C, Dietrich A, Li Z, Sawicki DR, Seestaller L, Wu L, Katz A, Sullivan D, Tio C, Zhang Z-Y: PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of nove; 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho [2,3-d]thiophenes. J Med Chem (1999) 42 (17):3199-3202.
62. Malamas MS, Sredy J, Moxham C, Katz A, Xu W, McDevitt R, Adebayo FO, Sawicki DR, Seestaller L, Sullivan D, Taylor JR: Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphate 1B with antihyperglycemic properties. J Med Chem (2000) 43(7):1293-1310.
63. Pei Z, Zinker BA, Gum RJ, Jacobson PB, Ballaron SJ, Trevillyan JM, Nguyen B, Marsh KC, Liu G, Xie NY, Jirousek M: (2R)-2-(2′,6′-Dichloro-4′-dibenzo[b,d]furan-4″-ylphenoxy )-3-phenylpropanoic acid (A-321842) as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with anti-diabetic effects in ob/ob mice. Diabetes (2001) 50(S1):1524-P.
64. PTP-112 drug report. Investigational Drugs Database March 14 (2002).
65. Bleasdale JE, Ogg D, Palazuk BJ, Jacob CS, Swanson ML, Wang W-Y, Thompson DP, Conradi RA, Mathews WR, Laborde AL, Stuchly CW et al: Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B (PTP1B) and augment insulin action. Biochemistry (2001) 40(19):5642-5654.
66. Larsen SD, Barf T, Liljebris C, May PD, Ogg D, O'Sullivan TJ, Palazuk BJ, Schostarez HJ, Stevens FC, Bleasdale JE: Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibito of protein tyrosine phosphatase 1B. J Med Chem (2002) 45(3):598-622.
67. Yao ZJ, King CR, Cao T, Kelley J, Milne GWA, Voigt JH, Burke TR: Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. J Med Chem (1999) 42(1):25-35.
68. Liljebris C, Larsen D, Ogg D, Palazuk BJ, Bleasdale JE: Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: Identification of a tetrazole-containing inhibitor with cellular activity. J Med Chem (2002) 45(9):1785-1798. A paper establishing cellular activity of PTP1B inhibition with a non-prodrug, small molecular inhibitor, and also highlighting the challenge in achieving better cellular permeability with highly charged inhibitors.
69. Andersen HS, Iversen LF, Jeppesen CB, Branner S, Norris K, Rasmussen HB, Moller NP: 2-(Oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases. J Biol Chem (2000) 275(10):7101-7108.
70. Iversen LF, Andersen HS, Branner S, Mortensen SB, Peters GH, Norris K, Olsen OH, Jeppesen CB, Lundt BF, Ripka W, Moller KB, Moller NP: Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B. J Biol Chem (2000) 275(14):10300-10307.
71. Peters GH, Iversen LF, Branner S, Andersen HS, Mortensen SB, Olsen OH, Moller KB, Moller NP: Residue 259 is a key determinant of substrate specificity of protein-tyrosine phosphatases 1B and α. J Biol Chem (2000) 275(24):18201-18209.
72. Iversen LF, Andersen HS, Moller KB, Olsen OH, Peters G H, Branner S, Mortensen SB, Hansen TK, Lau J, Ge Y, Holsworth DD et al: Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases. Biochemistry (2001) 40(49):14812-14820. Steucture-based design of non-peptide, low molecular weight, highly selective PTP1B inhibitor utilizing both
73. Hansen TK, Iversen LF, Lau J, Petersen AK, Olsen OH, Møller KB, Mortensen SB, Billestrup N, Ge Y, Newman M, Holsworth D et al: Potent non-peptide protein tyorsine phosphatase inhibitors. 223rd ACS National Meeting (200): MEDI-003
74. Liu G, Abad-Zapatero C, Szczpankiewicz B, Hajduk P, Pei Z, Xin Z, Janowick D, Liang H, Hutchins C, Ballaron S, Stashko M et al: Discovery of competitive, potent, and selective protein tyrosine phosphatase 1B inhibitors. 223rd ACS National Meeting (2002): MEDI-002.
75. Jirousek MR: Recent advances in PTP1B inhibitor design and as a therapeutic approach to treat Type 2 diabetes. Keystone Symposia in Diabetes Mellitus (200): Oral communication.
76. Novo Nordisk A/S/Ontogen Corp (Hansen TK, Lau J, Møller NPH, Olsen OH, Axe FU, Bakir F, Ge Y, Holsworth DD, Judge LM, Newman MJ, Uyeda RT, Shapira BZ): Modulators of protein tyrosine phosphatases (PTPases). WO-00204458 (2002).
77. Novo Nordisk A/S/Ontogen Corp (Andersen HS, Hansen TK, Lau J, Møller NPH, Olsen OH, Axe FU, Bakir F, Ge Y, Holsworth DD, Judge LM, Newman MJ, Uyeda RT, Shapira BZ): Modulators of protein tyrosine phosphatases (PTPases). WO-00204459 (2002).
78. Aventis Pharma (Petry S, Baringhaus K-H, Hoelder S, Mueller G): Substituted and non-substituted benzoxathiazoles and compounds derived therefrom. WO-00211722 (2002).
79. Sugen Inc (Huang P, Wei CC, Tang PC, Liang C, Ramphal J, Jallal B, Blitz J, Li S, Mattson MN, McMahon G, Koenig M): Phosphatae mimics and methods of treatment using phosphatase inhibitors. WO-00116097 (2001).